Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452543 · ClinicalTrials.gov registry record · Phase 4
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00452543: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00452543 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00452543, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will improve outcomes for this population.
Interventions
- DRUG Placebo
- BEHAVIORAL Medical management
- DRUG escitalopram
- DRUG acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00452543
The ClinicalTrials.gov registry entry for NCT00452543 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00452543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00452543 about?
NCT00452543 is a clinical study titled "Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism". This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will improve outcomes for this population.
What is the current status of trial NCT00452543?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2007-03. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00452543?
The interventions under investigation include: Placebo (DRUG), Medical management (BEHAVIORAL), escitalopram (DRUG), acamprosate (DRUG).
Who is sponsoring clinical trial NCT00452543?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.